Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies

Natural killer cells (NK cells) are the first line of the innate immune defense system, primarily located in peripheral circulation and lymphoid tissues. They kill virally infected and malignant cells through a balancing play of inhibitory and stimulatory receptors. In pre-clinical investigational s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Erica L. Heipertz, Evan R. Zynda, Tor Espen Stav-Noraas, Andrew D. Hungler, Shayne E. Boucher, Navjot Kaur, Mohan C. Vemuri
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	natural killer cells CAR-NK cells immunotherapy NK cell expansion lentiviral delivery AAV delivery Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/2d689492b6a441a5a28169b487703b68
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2d689492b6a441a5a28169b487703b68
record_format	dspace
spelling	oai:doaj.org-article:2d689492b6a441a5a28169b487703b682021-12-01T21:40:46ZCurrent Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies1664-322410.3389/fimmu.2021.732135https://doaj.org/article/2d689492b6a441a5a28169b487703b682021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.732135/fullhttps://doaj.org/toc/1664-3224Natural killer cells (NK cells) are the first line of the innate immune defense system, primarily located in peripheral circulation and lymphoid tissues. They kill virally infected and malignant cells through a balancing play of inhibitory and stimulatory receptors. In pre-clinical investigational studies, NK cells show promising anti-tumor effects and are used in adoptive transfer of activated and expanded cells, ex-vivo. NK cells express co-stimulatory molecules that are attractive targets for the immunotherapy of cancers. Recent clinical trials are investigating the use of CAR-NK for different cancers to determine the efficiency. Herein, we review NK cell therapy approaches (NK cell preparation from tissue sources, ways of expansion ex-vivo for “off-the-shelf” allogeneic cell-doses for therapies, and how different vector delivery systems are used to engineer NK cells with CARs) for cancer immunotherapy.Erica L. HeipertzEvan R. ZyndaTor Espen Stav-NoraasAndrew D. HunglerShayne E. BoucherNavjot KaurMohan C. VemuriFrontiers Media S.A.articlenatural killer cellsCAR-NK cellsimmunotherapyNK cell expansionlentiviral deliveryAAV deliveryImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	natural killer cells CAR-NK cells immunotherapy NK cell expansion lentiviral delivery AAV delivery Immunologic diseases. Allergy RC581-607
spellingShingle	natural killer cells CAR-NK cells immunotherapy NK cell expansion lentiviral delivery AAV delivery Immunologic diseases. Allergy RC581-607 Erica L. Heipertz Evan R. Zynda Tor Espen Stav-Noraas Andrew D. Hungler Shayne E. Boucher Navjot Kaur Mohan C. Vemuri Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
description	Natural killer cells (NK cells) are the first line of the innate immune defense system, primarily located in peripheral circulation and lymphoid tissues. They kill virally infected and malignant cells through a balancing play of inhibitory and stimulatory receptors. In pre-clinical investigational studies, NK cells show promising anti-tumor effects and are used in adoptive transfer of activated and expanded cells, ex-vivo. NK cells express co-stimulatory molecules that are attractive targets for the immunotherapy of cancers. Recent clinical trials are investigating the use of CAR-NK for different cancers to determine the efficiency. Herein, we review NK cell therapy approaches (NK cell preparation from tissue sources, ways of expansion ex-vivo for “off-the-shelf” allogeneic cell-doses for therapies, and how different vector delivery systems are used to engineer NK cells with CARs) for cancer immunotherapy.
format	article
author	Erica L. Heipertz Evan R. Zynda Tor Espen Stav-Noraas Andrew D. Hungler Shayne E. Boucher Navjot Kaur Mohan C. Vemuri
author_facet	Erica L. Heipertz Evan R. Zynda Tor Espen Stav-Noraas Andrew D. Hungler Shayne E. Boucher Navjot Kaur Mohan C. Vemuri
author_sort	Erica L. Heipertz
title	Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
title_short	Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
title_full	Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
title_fullStr	Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
title_full_unstemmed	Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
title_sort	current perspectives on “off-the-shelf” allogeneic nk and car-nk cell therapies
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/2d689492b6a441a5a28169b487703b68
work_keys_str_mv	AT ericalheipertz currentperspectivesonofftheshelfallogeneicnkandcarnkcelltherapies AT evanrzynda currentperspectivesonofftheshelfallogeneicnkandcarnkcelltherapies AT torespenstavnoraas currentperspectivesonofftheshelfallogeneicnkandcarnkcelltherapies AT andrewdhungler currentperspectivesonofftheshelfallogeneicnkandcarnkcelltherapies AT shayneeboucher currentperspectivesonofftheshelfallogeneicnkandcarnkcelltherapies AT navjotkaur currentperspectivesonofftheshelfallogeneicnkandcarnkcelltherapies AT mohancvemuri currentperspectivesonofftheshelfallogeneicnkandcarnkcelltherapies
_version_	1718404267693309952

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies

Ejemplares similares